BioSpace News Archive

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new late-breaking Phase 3b head-to-head data showing superior rates of skin clearance for SKYRIZI® (risankizumab-rzaa) to COSENTYX®

Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services, will be a virtual exhibitor and have several delegates attending the DIA Global Annual Meeting and Virtual Conference taking place June 14-18th, 2020

UCB, a global biopharmaceutical company, today announced the first presentations of data from the Phase 3 clinical development program of bimekizumab, its investigational IL-17A and IL-17F inhibitor, as part of a virtual session for the American Academy of Dermatology (AAD) 2020 Annual Meeting

Sees the COVID-19 Pandemic Continuing to Drive Broad User Demand for Smart Glasses Growing usage is notably evident across remote support, telemedicine and educational applications

Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” including its subsidiaries and/or associate companies) today announced that one of its wholly-owned subsidiaries presented data analyses for two of its specialty medicines – ODOMZO® (sonidegib) and LEVULAN® KERASTICK®

Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” including its subsidiaries and/or associate companies) today announced that one of its wholly owned subsidiaries presented further evidence of the long-term use and cost-effectiveness of ILUMYATM

Medtronic’s Advanced Hybrid Closed-Loop system use in adolescents and young adults with type 1 diabetes (T1D) can lead to improved daytime blood sugar control without an increase in hypoglycemia, according to research presented today at the American Diabetes Association’s® (ADA’s) 80th Scientific Sessions.

AbbVie (NYSE:ABBV) has been notified that TRC Capital Investment Corporation (TRC Capital) has commenced an unsolicited “mini-tender” offer, dated June 1, 2020 , to purchase up to 1,500,000 shares of AbbVie common stock at $88.05 per share. The offer price is approximately 4.99 percent below the closing price of the AbbVie co

Denmark study of self-reported data from more than 9,000 people finds overall need for better access to psychological and other non-medical diabetes care for people living with diabetes and their caregivers

The U.S. Food and Drug Administration continued to take action in the ongoing response to the COVID-19 pandemic